Medtronic's Smart MDI System Receives FDA Clearance for Enhanced Insulin Dosing
Key Insights
Medtronic's Smart MDI system, featuring the InPen (search)™ app and Simplera (search)™ CGM, has received FDA clearance, marking a significant advancement in diabetes (search) management.
The system is the first to offer real-time, personalized insights and correction recommendations for missed or inaccurate insulin doses, addressing a critical unmet need.
The Smart MDI system aims to reduce the guesswork in diabetes (search) management, helping to maintain stable blood sugar levels and reduce long-term complications for MDI users.
Medtronic has announced FDA clearance for its new InPen (search)™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera (search)™ continuous glucose monitor (CGM). The Smart MDI system combines the InPen™ smart insulin pen with the Simplera™ CGM, Medtronic's first disposable, all-in-one CGM, which is half the size of previous Medtronic CGMs.
With this clearance, the system will be the first in the market to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection (MDI) therapy. This advancement addresses a significant challenge for individuals with diabetes (search) who require daily insulin injections to regulate glucose levels and prevent blood sugar spikes after meals.
Addressing Missed Insulin Doses
Bolusing before a meal is essential for people with diabetes (search) as it helps regulate glucose levels and prevent blood sugar spikes after eating. Minimizing the frequency of these glucose highs reduces the risk of both short- and long-term complications and supports better overall health. However, it's estimated that individuals living with diabetes regularly miss 1 out of 3 doses. The Missed Dose alert function helps to minimize the frequency of these glucose highs. The Medtronic Smart MDI system reduces the guesswork out of diabetes management, helping to address a significant unmet need for MDI users who struggle with juggling numerous decisions related to insulin dosing on a daily basis.
Expert Commentary
"I'm thrilled about the launch of the Medtronic Smart MDI system with the InPen (search)™ app and Simplera (search)™ CGM. This is a significant leap forward for those on multiple daily injections, offering intelligent dosing insights and simplifying diabetes (search) management," said Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP. "By reducing the guesswork out of insulin dosing, this tool helps maintain stable blood sugars, optimize long-term health, and reduce complications from hyperglycemia (search)."
Launch Plans
Medtronic will initiate a limited market release beginning with existing standalone CGM and InPen (search)™ customers followed by a broad commercial launch.
About Medtronic Diabetes
Medtronic Diabetes (search) is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. They've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.